Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine

Vaccine. 1992;10(2):125-9. doi: 10.1016/0264-410x(92)90029-j.

Abstract

Sera from individuals across the USA and Peace Corps Volunteers (PCV) were assayed for neutralizing antibody to human diploid cell rabies vaccine (HDCV). A pairwise comparison between intramuscular (i.m.) and intradermal (i.d.) administration, PCV and non-PCV, revealed statistically significant differences between i.m. and i.d. for PCV and non-PCV, and between PCV and non-PCV for i.d. and i.m. administration. Survival analysis and frequency tables employing chi 2 tests determined that the percentage probability of maintaining an adequate titre from 1.5-2.0 years after primary vaccination was 99% in non-PCV i.m., 93% in non-PCV i.d., 88% in PCV i.m., and 64% in PCV i.d.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Viral / blood*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Injections, Intradermal
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Rabies Vaccines / administration & dosage
  • Rabies Vaccines / immunology*
  • Rabies virus / immunology*
  • Time Factors

Substances

  • Antibodies, Viral
  • Rabies Vaccines